LEADER 01419nam--2200481---450 001 990000826530203316 005 20200518103109.0 010 $a88-7835-114-8 035 $a0082653 035 $aUSA010082653 035 $a(ALEPH)000082653USA01 035 $a0082653 100 $a20020102h1991----km-y0itay0103----ba 101 $aita 102 $aIT 105 $a||||||||001yy 200 1 $a<> pscologia e la vita$fHugo Münsterberg$ga cura di Edoardo Massimilla 210 $aNapoli$cGuida$d1991 215 $a115 p$d23 cm 225 2 $aMicromegas$v34 312 $aPsychology and life 410 $12001$v34 454 $12001$aPsychology and life$939989 676 $a152 700 1$aMÜNSTERBERG,$bHugo$f<1863-1916>$0435822 702 1$aMASSIMILLA,$bEdoardo 801 0$aIT$bsalbc$gISBD 912 $a990000826530203316 951 $aII.1 Coll.26/ 29(IV A COLL. 44 34)$b136658 LM$cIV A COLL. 951 $aAA 152 MUN$b804 FIL 959 $aBK 969 $aUMA 969 $aFIL 979 $aPATTY$b90$c20020102$lUSA01$h1037 979 $c20020403$lUSA01$h1728 979 $aPATRY$b90$c20040406$lUSA01$h1657 979 $aCOPAT5$b90$c20050601$lUSA01$h1541 979 $aANNAMARIA$b90$c20110411$lUSA01$h0930 979 $c20121027$lUSA01$h1545 979 $c20121027$lUSA01$h1604 979 $c20121027$lUSA01$h1610 996 $aPsychology and life$939989 997 $aUNISA LEADER 02093oam 2200589 450 001 9910716944103321 005 20211130090506.0 035 $a(CKB)5470000002526756 035 $a(OCoLC)976037641 035 $a(EXLCZ)995470000002526756 100 $a20170316d2016 ua 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBathymetric and velocimetric surveys at highway bridges crossing the Missouri River near Kansas City, Missouri, June 2--4, 2015 /$fby Richard J. Huizinga 210 1$aReston, Virginia :$cU.S. Department of the Interior, U.S. Geological Survey,$d2016. 215 $a1 online resource (ix, 93 pages) $ccolor illustrations, color maps 225 1 $aScientific investigations report,$x2328-0328 ;$v2016-5061 300 $a"Prepared in cooperation with the Missouri Department of Transportation." 320 $aIncludes bibliographical references (pages 70-71). 606 $aStream measurements$zMissouri$zKansas City 606 $aBridges$zMissouri$zKansas City 606 $aStreamflow$xTesting 606 $aScour at bridges 606 $aScour at bridges$2fast 606 $aStream measurements$2fast 607 $aMissouri River 607 $aMissouri$zKansas City$2fast 607 $aMissouri River$2fast 615 0$aStream measurements 615 0$aBridges 615 0$aStreamflow$xTesting. 615 0$aScour at bridges. 615 7$aScour at bridges. 615 7$aStream measurements. 700 $aHuizinga$b Richard J.$01388712 712 02$aMissouri.$bDepartment of Transportation. 712 02$aGeological Survey (U.S.), 801 0$bMODOT 801 1$bMODOT 801 2$bOCLCO 801 2$bOCLCQ 801 2$bOCLCO 801 2$bOCLCF 801 2$bMODOT 801 2$bGPO 906 $aBOOK 912 $a9910716944103321 996 $aBathymetric and velocimetric surveys at highway bridges crossing the Missouri River near Kansas City, Missouri, June 2--4, 2015$93506542 997 $aUNINA LEADER 05469nam 2200673 450 001 9910819754603321 005 20230803195556.0 010 $a1-118-49402-4 010 $a1-118-49398-2 010 $a1-118-49401-6 035 $a(CKB)2670000000546973 035 $a(EBL)1652083 035 $a(SSID)ssj0001131703 035 $a(PQKBManifestationID)11729001 035 $a(PQKBTitleCode)TC0001131703 035 $a(PQKBWorkID)11142629 035 $a(PQKB)10006575 035 $a(OCoLC)867001329 035 $a(MiAaPQ)EBC1652083 035 $a(DLC) 2013051093 035 $a(Au-PeEL)EBL1652083 035 $a(CaPaEBR)ebr10851659 035 $a(CaONFJC)MIL584452 035 $a(OCoLC)874322105 035 $a(EXLCZ)992670000000546973 100 $a20140408h20142014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAntiplatelet therapy in cardiovascular disease /$fedited by Ron Waksman, Paul A. Gurbel, Michael A. Gaglia, Jr 210 1$aChichester, West Sussex, United Kingdom :$cJohn Wiley & Sons,$d2014. 210 4$d©2014 215 $a1 online resource (349 p.) 300 $aDescription based upon print version of record. 311 $a1-118-27575-6 320 $aIncludes bibliographical references and index. 327 $aAntiplatelet Therapy in Cardiovascular Disease; Copyright; Contents; List of Contributors; Foreword; Preface; Section I Platelet Biology and Pathophysiology; 1 Platelet Pathophysiology and its Role in Thrombosis; Role of platelets during initiation of atherosclerosis and plaque formation; Role of platelets in thrombosis; References; 2 Platelet Receptors and Drug Targets: COX-1; Structure, expression, and catalytic activity of platelet COX-1; Functional role of platelet COX -1; Genetic polymorphisms of COX-1 and COX-2 expression in platelets 327 $aPlatelet COX-1 as a target for antithrombotic therapyInteraction between aspirin and naNSAIDs at the level of platelet COX-1; In vitro and in vivo evidence for aspirin/naNSAID interaction; Concluding remarks; References; 3 Platelet Receptors and Drug Targets: P2Y12; P2 receptors; Roles of adenine nucleotides in platelet function; P2Y12; Conclusions; References; 4 Platelet Receptors and Drug Targets: GP IIb/IIIa; Introduction; Biology of the receptor; Glycoprotein IIb/IIIa receptor in platelet physiology; Platelet aggregation phase; "Inside-out" and "outside-in" GPIIb/IIIa signaling phenomenon 327 $aGlycoprotein IIb/IIIa receptor and thrombus formationGlycoprotein IIb/IIIa receptor antagonists; Intravenous versus oral preparations: clinical aspects; Acknowledgment; References; 5 Platelet Receptors and Drug Targets: PAR1, Collagen, vWF, Thromboxane, and Other Novel Targets; Introduction; Protease-activated receptor 1 (PAR1); References; 6 Role of Inflammation and Hypercoagulability in Thrombosis; References; Section II Platelet Function Tests; 7 Light Transmission Aggregometry; Technique; References; 8 Vasodilator-Stimulated Phosphoprotein (VASP) Assay; Introduction; The VASP index assay 327 $aVASP index and clinical eventsAlteration of antiplatelet therapy based on the VASP index; VASP index and new oral antiplatelet agents; Conclusions; References; 9 VerifyNow P2Y12 and Plateletworks Assays; Introduction; Verifynow P2Y12; Plateletworks; Validity of the test in measuring antiplatelet effect and its association with clinical outcomes; Conclusion; References; 10 Multiplate Analyzer; Historical background; Principles of the Multiplate® analyzer; Advantages; Disadvantages; Clinical studies in cardiovascular medicine; Studies in cardiovascular surgery 327 $aConsensus definitions and cutoff values concerning platelet reactivitySummary; Acknowledgment; References; 11 Shear Stress-Based Platelet Function Tests; PFA-100; IMPACT-R; References; 12 Thrombelastography and Other Novel Techniques; Novel techniques; T2 magnetic resonance (T2MR); Shear-induced platelet aggregation assays; References; Section III Antiplatelet pharmacology; 13 Aspirin; Mode of antiplatelet action; Time dependency of inhibition of platelet function by aspirin; Dose-dependent inhibition of platelet function by aspirin; Negative interactions with other drugs 327 $aPositive interactions with other drugs 330 $a Edited by one of the world's leading interventional cardiologists and educators, this new book is created with an eye on giving the reader a solid, practical and clinically-focused understanding of this important class of drugs, from basic science to a clear-headed discussion of complex topics such as combination therapies, drug-drug interactions, and platelet resistance. This important new book: Begins with a concise but thorough discussion of platelet biology and pathophysiology so that readers understand how these therapies work and why they can also produce such a varied 606 $aCardiovascular system$xDiseases 606 $aCardiovascular system$xDiseases$xPrevention 615 0$aCardiovascular system$xDiseases. 615 0$aCardiovascular system$xDiseases$xPrevention. 676 $a616.1/061 702 $aWaksman$b Ron 702 $aGurbel$b Paul A. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910819754603321 996 $aAntiplatelet therapy in cardiovascular disease$94024951 997 $aUNINA